简介:目的:探讨彩色超声波导向射频毁损联合瘤内无水酒精注射治疗原发性肝癌的治疗效果和安全性.方法:应用彩超引导下对130例原发性肝癌患者进行射频毁损联合瘤内无水酒精治疗和对103例肝癌患者进行射频治疗.比较观察该法治疗组与单纯射频治疗组治疗前后肿瘤大小、血供变化与临床疗效的关系.结果:该法治疗组与单纯射频治疗组术后肿瘤血供消失和减少率分别为96.1%和67.9%;3个月复查彩超肿瘤缩小25%以上者分别为89.2%和81.5%.结论:射频毁损联合无水酒精注射是一种有效治疗肝癌的新方法.同时,彩超为实时观察肝癌血供状态、声像图变化提供重要依据,在指导治疗和判定疗效方面有重要意义.
简介:Objective:TheUnionforInternationalCancerControl(UICC)Node(N)classificationisthemostcommonusedstagingmethodfortheprognosisofgastriccancer.Itdemandsadequate,atleast16lymphnodes(LNs)tobedissected;thereforedifferentstagingsystemswereinvented.Methods:BetweenMarch2005andMarch2010,164patientswereevaluatedattheDepartmentofGeneralSurgeryintheKenézyGyulaHospitalandattheDepartmentofGeneral,ThoracicandVascularSurgeryintheKaposiMórHospital.The6th,7thand8thUICCN-stagingsystems,thenumberofexaminedLNs,thenumberofharvestednegativeLNs,themetastaticlymphnoderatio(MLR)andthelogoddsofpositiveLNs(LODDS)weredeterminedtomeasuretheir5-yearsurvivalratesandtocomparethemtoeachother.Results:Theoverall5-yearsurvivalrateforallpatientswas55.5%withamedianoverallsurvivaltimeof102months.Thetumorstage,gender,UICCN-stages,MLRandtheLODDSweresignificantprognosticfactorsforthe5-yearsurvivalwithunivariateanalysis.The6thUICCN-stagedidnotfollowtheadequateriskincomparingN2vs.N0andN3vs.N0withmultivariateinvestigation.ComparisonofperformancesoftheresidualNclassificationsprovedthattheLODDSsystemwasfirstinthepredictionofprognosisduringtheevaluationofallpatientsandincaseswithlessthan16harvestedLNs.TheMLRgavethebestprognosticpredictionwhenadequate(morethanorequalto16)lymphadenectomywasperformed.Conclusions:WesuggesttheapplicationofLODDSsystemroutinelyinwesternpatientsandtheusageofMLRclassificationincaseswithextendedlymphadenectomy.
简介:目的:探讨多种超声成像形式联合计分法评估乳腺BI-RADS 4/5类结节良恶性的价值。资料与方法:回顾性分析本院收集的614个乳腺BI-RADS 4/5类结节病例,应用计分法把彩色多普勒血流显像(Color dopple flow imaging,CDFI)、声触诊组织成像(Virtual touch tissue imaging,VTI)、声触诊组织量化技术(Virtual touch tissue quantification,VTQ)、超声造影(Contrast Enhanced Ultrasound,CEUS)以及联合应用等多种超声成像形式联合诊断共分成5组,各以良性记0分,可疑记1分,恶性记2分,联合诊断将各单独成像诊断模式计分相加,以≥5分评估为恶性,≤3分评估为良性,4分评估为可疑;分别计算CDFI、VTI、VTQ、CEUS、联合诊断等多种超声成像形式联合计分法诊断乳腺良恶性结节的敏感性、特异性、准确性。结果:1、CDFI、VTI、VTQ、CEUS及联合诊断计分法鉴别乳腺结节良恶性差异均具有统计学意义(p<0.05);2、CDFI、VTI、VTQ、CEUS及联合计分法诊断乳腺良恶性结节的敏感性分别为71.1%、66.9%、83.5%、85.1%、94.2%;特异性分别为52.3%、41.4%、87.6%、87.1%、95.7%;准确性分别为73.4%、51.1%、86.3%、87.6%、93.8%;3、绘制CDFI、VTI、VTQ、CEUS及联合诊断共5组多种超声成像模式ROC曲线,曲线下面积分别为:0.877、0.596、0.889、0.907、0.920,并ROC曲线两两对比,其中CDFI与VTQ、CDFI与CEUS、VTQ与CEUS、CEUS与联合比较(z=0.737、1.226、0.669、0.703,p=0.4611、0.2204、0.5034、0.4821),差异无统计学意义(p>0.05),其余差异均具有统计学意义(p<0.05);结论:多种超声成像形式联合计分法诊断可互相补充,提高乳腺BI-RADS 4/5类结节的鉴别诊断水平。
简介:PROMOTIONOFINVITROGROWTHOFHUMANMEDULLOBLASTOMACELLSBYEXOGENEOUSIL-6LiuJiai刘佳;LiHong李宏;HamouMarie-France;NicolasdeTribolet(1Di...
简介:N^6-methyladenosine(m^6A)isanessentialRNAmodificationthatregulateskeycellularprocesses,includingstemcellrenewal,cellulardifferentiation,andresponsetoDNAdamage.Unsurprisingly,aberrantm6Amethylationhasbeenimplicatedinthedevelopmentandmaintenanceofdiversehumancancers.Alteredm6AlevelsaffectRNAprocessing,mRNAdegradation,andtranslationofmRNAsintoproteins,therebydisruptinggeneexpressionregulationandpromotingtumorigenesis.Recentstudieshavereportedthattheabnormalexpressionofm6Aregulatoryenzymesaffectsm6Aabundanceandconsequentlydysregulatestheexpressionoftumorsuppressorgenesandoncogenes,includingMYC,SOCS2,ADAM19,andPTEN.Inthisreview,wediscussthespecificrolesofm6A“writers",“erasers”,and“readers”innormalphysiologyandhowtheiralteredexpressionpromotestumorigenesis.Wealsodescribethepotentialofexploitingtheaberrantexpressionoftheseenzymesforcancerdiagnosis,prognosis,andthedevelopmentofnoveltherapies.
简介:Objective:Toexploretheprobabilityofvascularendothelialgrowthfactor(VEGF)antisenseoligodeoxynucleotidesasadevelopingnewtherapeuticstrategyforglioma.Methods:VEGFproteinexpressionwasdetectedbyS-Pimmunohistochemicaltechnique.TumorcellapoptosiswasobservedbyTUNELmethod.Results:Comparedwithcontrol,VEGFproteinexpressionwasinhibitedbyantisenseoligodeoxynucleotidesinvitro.Andtheinhibitoryeffectsincreasedwiththeincreasingconcentration.VEGFpositiveratewas82.10%incontrolgroup,whilein2.5,5,10(mol/LAODNgroups,theywere70.00%,57.85%,53.20%respectively.Noinhibitioneffectwasfoundinthecelllinestreatedwithmissenseandsenseoligodeoxynucleotides.Invivo,antisenseoligodeoxy-nucleotidestherapyalsoinhibitedVEGFproteinexpressionandinducedtheincreaseofapoptotictumorcells.However,ithasnoeffectontumorcellproliferation.Conclusion:ItishopefulthatVEGFantisenseoligodeoxynucleotidesmaybeanewgenetherapymethodtogliomathroughitsantiangiogenesiseffectbyinhibitionofVEGF.
简介:背景与目的:原发性椎管内淋巴瘤十分罕见,本研究旨在总结原发椎管内淋巴瘤的临床特点,影像学特征及治疗手段,以提高对此病的认识。方法:对北京天坛院神经外科三病房2000年1月至2006年12月间收治的6例经病理证实为椎管内恶性淋巴瘤的患者进行回顾性分析,并文献复习。结果56例患者中,男性4例,女性2例,中位年龄38.5岁。4例患者首发症状为疼痛,平均病程10.9个月。所有患者术前均行MRI检查.肿瘤位于颈段4例,胸段1例,骶段1例。本组患者均采取显微手术治疗,术中辅以电生理监测,肉眼全切1例,近全切除4例,大部分切除1例,无手术死亡。术后4例症状缓解,出院后全部患者均行放射治疗.效果满意。结论:原发性椎管内淋巴瘤是椎管内的罕见肿瘤,缺乏特异性的影像学表现。椎板切除减压,肿瘤切除.术后辅以局部放疗和全身化疗是其主要治疗手段.预后较好。
简介:Objective:Tostudytheroleofconnexingene(Cx43)onthedevelopmentofgliomaandthefeasibilityofusingCx43cDNAasatargetofgenetherapyofgliomas.Methods:ParentalratC6cellsandC6cellstransfectedwithCx43cDNAwereimplantedintorightcaudatenucleusofSDratsascontrolandtransfectedgroup.RatsbearingcerebralC6gliomasweretreatedwithCx43cDNAandemptyvectorastreatedgroupandemptyvectorgroup.Thegeneralmanifestation,survivaltime,MRIdynamicscanningandhistopathologicalchangesofallratswereobserved.Insituhybridizationandimmunohisto-chemistrywereusedforexaminationofCx43mRNAanditsproteiningliomas.AveragenumberofAgNORstainingwasusedfordetectionofcellproliferationactivity,andTUNELmethodfordeterminationofcellapoptosis.Results:Allratsincontrolandemptyvectorgroupdiedofcerebralgliomaswithin3weeksafterimplantationofC6cells.Sixoutofnineratsinthetransfectedgroupandeightoutoftenratsintreatedgroupkeptalivebeyond120dayswithtotallydisappearingofthetumorfoci,exceptonetreatedrathavingalittleresidueoftumor.IngliomasoftransfectedandtreatedgroupsCx43geneexpressionwasupregulated,proliferationactivitywaslowered,However,theapoptoticcellsdidnotincrease.Conclusion:ThepresentstudyindicatesthatCx43geneisofcrucialimportanceinthedevelopmentofmalignantglioma.Itcanbeaneffectivetargetforgenetherapyofgliomas.
简介:Objective:Toinvestigatetheimmunotherapyefficacyoffusioncells(dendritic-C6anti-TGF-β1cells)inthetreatmentofintracranialgliomas.Methods:Dendriticcellswereisolatedfromratbone-marrowprecursorsstimulatedinvitrowithgranulocyte-macrophagecolony-stimulatingfactor(GM-CSF)andInterleukin-4(IL-4).C6anti-TGF-β1cellsoriginallyfromC6celllineofaratglioblastomaweretransfectedwithplasmidofTGF-β1anti-sensegene.FusionsofdendriticcellsandC6anti-TGF-β1cellswerepreparedbypolyethyleneglycol(PEG).TheDC/C6anti-TGF-β1fusioncellswereobservedandconfirmedbylightmicroscopyandscanningelectronmicroscopy.Experimentalratsweredividedintothreegroupsatrandom:C6cells(I),dendritic-C6anti-TGF-β1fusioncellsandC6cells(II)andIMDMmediumonly(III).Thecellswereinjectedintorightparietalloberegionoftheratwithstereotaxictechnique.Histology,tumornecrosisandsurvivaltimewereevaluated.Results:ComparedwiththeratsthatreceivedC6cells(survivalmediantimewaslessthan20days,tumorregionwasseeninallfieldsofobserved),theratsinjectedwithdendritic-C6anti-TGF-β1fusioncellsandC6cellsgotamoreprolongedlifespan(morethan59days),aswellaslesstumorregion(5.01%-6.2%).Therewasnotumornecrosis,butsomegliaswereseeninsurroundings.Allratsweresurvivedandnonecrosiswasobservedinnegativecontrolgroup.StatisticalanalysisshowedthatgroupIIhadsignificantdifferencecomparedwithgroupI.Conclusions:Dendritic-C6anti-TGF-β1fusioncellscouldprolongthelifespanofrats,providingastrategytoachieveanantitumorresponseagainsttumorsinthecentralnervoussystem.
简介:客观:为了与M-CSFR验证MAF-J6-1受体的抗原协会并且进一步学习M-CSF和它的受体的角色,调停了在支持白血病的房间增长的juxtacrine。方法:MAF-J6-1RRE2的Monoclonal抗体(McAb)和rhM-CSFR的polyclonal抗体(PolyAb)被准备。到M-CSFR的McAbRE2的特性被ELISA被间接ELISA,有J6-1房间殖民地形成的跨neutralizing试金和中立化测试证实。结果:到M-CSFR的净化的RE2的反应活动是超过1:16000。M-CSFR和MAF-J6-1R的禁止的活动能被RE2和anti-M-CSFR抗体堵住。到M-CSFR的RE2的反应能被M-CSFR减少。结论:到M-CSFR的RE2的特性被证实,有M-CSFR的MAF-J6-1R的抗原协会被证明。它建议M-CSF和它的受体调停了auto-juxtacrine刺激能是在白血病或nonhematological恶意的起作用的机制。
简介:目的:探讨血管内皮生长因子(VEGF)、CD44v6在非小细胞肺癌(NSCLC)的表达及其临床意义。方法:采用SP免疫组织化学方法观察VEGF、CD44v6在62例NSCLC组织的表达。结果:VEGF、CD44v6在NSCLC组织中表达阳性率分别为72.6%、69.4%,均明显高于癌旁正常组织,P<0.01。VEGF、CD44v6的表达与临床分期及有无淋巴结转移有明显相关,有淋巴结转移组其阳性率明显高于无淋巴结转移组,Ⅲ-Ⅳ期NSCLC组织中VEGF、CD44v6均明显高于Ⅰ-Ⅱ期,P<0.05。VEGF、CD44v6阳性的患者3a生存率均明显低于阴性者,P<0.05。通过COX回归分析发现TNM临床分期、CD44v6阳性表达、有无淋巴结转移及VEGF阳性表达可以作为独立的因素影响NSCLC患者术后的3a生存率。结论:通过这两个指标的检测,可以初步预测NSCLC患者的预后及指导其临床治疗。
简介:目的探讨CD44V6在肠癌组织中的表达及与血管形成的关系。方法应用免疫组化方法检测CD44V6、MVD在57例大肠腺癌、16例腺瘤癌变、62例肠腺瘤及17例正常黏膜中的表达情况并进行分析。结果CD44V6的阳性表达率在腺癌中为45.6%(26/57),腺瘤为58.1%(36/62),腺瘤恶变为75.0%(12/16),正常黏膜为5.9%(1/17);腺癌中MVD值为24.65±7.84。腺癌中CD44V6与MVD的表达有明显的相关性(P〈0.01),而且二者的表达与肿瘤的大小、淋巴结转移、浸润深度与分化程度密切相关。结论CD44V6在肠癌的表达与肿瘤血管形成密切相关,联合检测CD44V6与MVD将有助于筛选具有浸润复发转移的肿瘤,可作为一项辅助指标用于估测预后及指导治疗。
简介:背景与目的:颅内血管外膜细胞瘤(hemangiopericytoma,HPC)发病率低,临床诊治困难,本研究旨在提高对颅内HPC的认识。方法:回顾总结6例颅内HPC患者的临床表现、影像、病理特点以及手术切除和预后情况,并且复习相关文献。结果:6例患者均行开颅手术治疗,其中全切除4例,近全切除2例;术后5例行放射治疗,1例拒绝放疗。术后随访1~10个月,尚未发现肿瘤复发及转移。结论:颅内HPC生长活跃,血供丰富,尤其是位于大脑镰及矢状窦旁时,因此要明确诊断,做好充分的术前准备:手术切除是最佳的治疗手段。应尽量全切,切除范围要广泛.放射治疗是主要的辅助治疗手段。
简介:Asyntheticpolypeptide,pt27,whichisencodedbyacDNAclonewithantloncogeneactivity,p14-6,isfoundtobeabletoreduceremarkablythesoftagarcolonyformationabilityofpartofDTcellsandtoraisetheirresistancetotheouabalntoxtcity.Thisshowsthatthept27peptidecanaffecttheDTcellsInamannersimilartothep14-6doneandprovidesevidencethattherevertingactionofthep14-6toDTcellsmaybeexertedbytheexpressionofitscDNA.